Résultats du concours de avril 2014 pour les subventions pour l’ innovation

Nous avons le plaisir d’annoncer les résultats du plus récent concours de bourses pour l'innovation. Ce concours vise à appuyer des initiatives de recherche uniques et créatives contre le cancer. Voici une liste des bourses pour l’innovation qui ont été accordées récemment par la Société canadienne du cancer et nos partenaires.

Sur un total de 229 demandes de subventions pour l’innovation, 51 ont été approuvées, pour un taux de succès de 22 %. Le budget maximal de chaque subvention a été fixé à 200 000 $ sur trois ans. L’ensemble des 51 subventions constitue un investissement global de presque de 10 millions dollars sur toute la durée des projets. Le nombre de subventions accordées est plus élevé que prévu en raison de la qualité des projets soumis lors de cette compétition.

Nous souhaitons remercier la Lotte and John Hecht Memorial Foundation d’avoir apporté leur soutien aux bourses de ce concours énumérées ci-dessous.

Nous nous réjouissons également que chaque projet ait pu être financé à la hauteur recommandée par le comité et qu'aucune déduction administrative n’a été appliquée.

Résumés des bourses attribuées (en anglais seulement)

Résumés des bourses attribuées au Québec (en français)

 

Remarques :
  • Les sommes indiquées ci-dessus représentent le montant total en dollars accordé par année de subvention et peuvent comprendre des fonds réservés aux salaires, aux fournitures et à l’équipement. 
  • La date de début de ces bourses est le 1er août 2014. 
  • Seul le nom du chercheur principal apparaît dans la liste. Le chercheur principal associé, les codemandeurs et les auteurs supplémentaires peuvent être associés à ces bourses.
Note importante :

Bien que nous ayons pris toutes les précautions pour assurer l'exactitude de la liste présentée ci-dessus, celle-ci n'a pas valeur d'avis officiel.

Les gagnants du concours de bourses recevront une notification écrite officielle de bourse dans laquelle figureront les détails relatifs à celle-ci.

Candidat
Établissement
Titre
Subvention
Arnaout, Angel
Ottawa Hospital Research Institute
The specimen margin assessment technique (SMART) Trial : A novel 3D method of identifying the most accurate method of specimen orientation in breast cancer surgery

*co-financement offert par Lotte and John Hecht Memorial Foundation

2014/2015 :  $68,388
2015/2016 :  $62,757
Barrera, Maru
Hospital for Sick Children
Improving quality of life in children with cancer through psychosocial screening and improved communication in health care providers
*co-financement offert par Lotte and John Hecht Memorial Foundation
2014/2015 :  $99,771
2015/2016 :  $99,974
Bedard, Philippe
Ontario Cancer Institute/PMCC - UHN
Molecular basket trial in multiple malignancies with common target pathway aberrancies (MOBILITY-002)
2014/2015 :  $65,868
2015/2016 :  $65,868
2016/2017 :  $65,870
Borden, Katherine
University of Montreal
The eukaryotic translation initiation factor eIF4E regulates a new level of mRNA metabolism
2014/2015 :  $100,000
2015/2016 :  $100,000
Bottorff, Joan
University of British Columbia (Okanagan)
Dads in Gear: An Innovative Men-centred Approach to Smoking Cessation
2014/2015 :  $99,996
2015/2016 :  $100,000
Bremner, Rod
Mount Sinai Hospital
Influence of cell death on cancer initiation
*financement offert par Lotte and John Hecht Memorial Foundation
2014/2015 :  $100,000
2015/2016 :  $100,000
Caperchione, Cristina
University of British Columbia
If THEY build it, will THEY act? Novel approaches to increasing physical activity among breast cancer survivors
*financement offert par Lotte and John Hecht Memorial Foundation
2014/2015 :  $77,940
2015/2016 :  $92,650
2016/2017 :  $29,190
Chi, Kim
BC Cancer Agency (Vancouver)
Genomic profiling of circulating tumour DNA (ctDNA) as a predictive biomarker for patients with castration resistant prostate cancer (CRPC)
2014/2015 :  $99,650
2015/2016 :  $99,650
Côté, Jean-François
IRCM - Institut de Recherches Cliniques de Montréal (affil. U de Montreal)
Investigating the roles of a subset of oncogene-induced Interferon Type I genes in HER2 breast cancer metastasis
2014/2015 :  $100,000
2015/2016 :  $100,000
Craig, Andrew
Queen's University
Targeting receptors that drive cancer metastasis using synthetic antibodies
2014/2015 :  $96,899
2015/2016 :  $96,899
Davie, James
University of Manitoba
Nuclear RNA and PRDX1
2014/2015 :  $98,300
2015/2016 :  $99,510
Dick, Frederick
Western University
Disrupting cell cycle arrest to kill dormant metastases
2014/2015 :  $100,000
2015/2016 :  $100,000
Dumeaux, Vanessa
McGill University
Interactions between the tumour-microenvironment and the systemic response of breast cancer patients
2014/2015 :  $81,660
2015/2016 :  $98,400
2016/2017 :  $19,800
Eaves, Connie
BC Cancer Agency (Vancouver)
Development of a new system to analyze the initial process of human breast cancer development
2014/2015 :  $100,000
2015/2016 :  $100,000
Fish, Jason
The Toronto Hospital (General Division) - UHN
Control of tumour growth by circulating anti-inflammatory microRNAs
2014/2015 :  $99,965
2015/2016 :  $99,965
Foulkes, William
Lady Davis Institute (affil. McGill)
Towards a biological understanding of small cell carcinoma of the ovary, hypercalcemic type
2014/2015 :  $100,000
2015/2016 :  $100,000
Frappier, Lori
University of Toronto
Epigenetic-based therapeutic approaches for Epstein-Barr Virus-induced cancers
2014/2015 :  $100,000
2015/2016 :  $100,000
Gibbings, Derrick
University of Ottawa
Autophagy degrades circular RNAs to control microRNAs and invasion of breast cancer cells
2014/2015 :  $99,964
2015/2016 :  $99,964
Guidos, Cynthia
Hospital for Sick Children
Single cell biomarkers for pathway-targeted leukemia therapies
2014/2015 :  $100,000
2015/2016 :  $100,000
Hirasawa, Ken
Memorial University of Newfoundland
Exploiting modulation of PpIX accumulation by Ras/MEK: an innovative approach towards photodynamic therapy.
2014/2015 :  $59,666
2015/2016 :  $73,166
2016/2017 :  $67,168
Hoang, Trang
University of Montreal
Towards a targeted and mechanism-based therapy in T-cell leukemia
2014/2015 :  $100,000
2015/2016 :  $100,000
Hui, Chi-chung
Hospital for Sick Children
Roles of Spop and Spopl in medulloblastoma
2014/2015 :  $100,000
2015/2016 :  $99,279
Ilangumaran, Subburaj
Universite de Sherbrooke
Enhancing tumour immunogenicity using NOD-like receptor family CARD domain containing protein 5 (NLRC5)
2014/2015 :  $100,000
2015/2016 :  $100,000
Jan, Eric
University of British Columbia
Effective development and translations of therapeutics mRNA in hypoxic tumours
2014/2015 :  $100,000
2015/2016 :  $100,000
Jiang, Xiaoyan
BC Cancer Agency (Vancouver)
A novel treatment approach to overcome TKI resistance in CML
2014/2015 :  $100,000
2015/2016 :  $100,000
Kim, Philip
University of Toronto
Discovery and validation of novel cancer drug targets using large peptide lentiviral libraries
2014/2015 :  $99,964
2015/2016 :  $99,964
Lewis, John
University of Alberta
miRNA-based biofluid diagnostics to predict prostate cancer metastasis
2014/2015 :  $100,000
2015/2016 :  $100,000
Li, Yingfu
McMaster University
Development of a Noninvasive Method for Early Colorectal Cancer Detection
2014/2015 :  $99,825
2015/2016 :  $99,825
Lupien, Mathieu
Ontario Cancer Institute/PMCC - UHN
Identifying the changes to the chromatin landscape imposed by genetic predispositions in breast cancer
2014/2015 :  $100,000
2015/2016 :  $100,000
Martel, Anne
Sunnybrook Research Institute
Quantitative assessment of tumour burden in breast cancer
2014/2015 :  $62,220
2015/2016 :  $85,113
2016/2017 :  $51,640
Masson, Jean-Yves
Laval University
APRIN: A novel regulator of DNA repair and tumour suppression in breast and ovarian cancer
2014/2015 :  $66,666
2015/2016 :  $66,666
2016/2017 :  $66,666
McEwen, Sara
Sunnybrook Research Institute
Development and pilot evaluation of a rehabilitation consult for survivors of head and neck cancer
2014/2015 :  $96,000
2015/2016 :  $95,930
Mes-Masson, Anne-Marie
Centre de recherche du CHUM - Pav. Notre-Dame (affil U de Montreal)
Microfluidic based empirical testing versus predictive biomarkers to stratify cancer care in ovarian cancer patients
2014/2015 :  $100,000
2015/2016 :  $97,750
Minden, Mark
Ontario Cancer Institute/PMCC - UHN
Identification of alternatives to steroid therapy in lymphoid malignancies
2014/2015 :  $100,000
2015/2016 :  $100,000
Mossman, Karen
McMaster University
Combining oncolytic HSV with ICD-inducing chemotherapeutics in a spontaneous breast tumour model
*co-financement offert par Lotte and John Hecht Memorial Foundation
2014/2015 :  $97,615
2015/2016 :  $100,000
Nepveu, Alain
McGill University
Exploiting DNA repair properties of cancer cells
2014/2015 :  $99,631
2015/2016 :  $99,631
Pelletier, Jerry
McGill University
Functional analysis of cancer genomes using a Cas9-based engineering platform
2014/2015 :  $100,000
2015/2016 :  $100,000
Roberge, Michel
University of British Columbia
Chemical suppressors of nonsense mutations in cancer
2014/2015 :  $99,921
2015/2016 :  $99,921
Roux, Philippe
University of Montreal
Role of CK1 in tumour growth and resistance
2014/2015 :  $99,000
2015/2016 :  $99,000
Santos, Manuela
Centre hospitalier de l'Université de Montréal
Colon cancer and inflammation: the interplay of iron, microbiota and host at the mucosal interface
2014/2015 :  $60,000
2015/2016 :  $60,000
2016/2017 :  $60,000
Shoichet, Molly
University of Toronto
Cancer drug delivery via self-aggregation into colloidal nano-particles
2014/2015 :  $100,000
2015/2016 :  $100,000
Sidhu, Sachdev
University of Toronto
Engineered ubiquitin variants for selective modulation of p53 activity
2014/2015 :  $99,987
2015/2016 :  $99,987
Siegel, Peter
McGill University
Control of focal adhesion dynamics in metastatic breast cancer
2014/2015 :  $59,000
2015/2016 :  $69,500
2016/2017 :  $71,500
Steinberg, Gregory
McMaster University
Defining the roles of systemic and direct tumour effects of biguanides to optimize treatment
2014/2015 :  $100,000
2015/2016 :  $100,000
Tabori, Uri
Hospital for Sick Children
Utilization of THOR hypermethylation for stratification and noninvasive detection of cancer.
2014/2015 :  $99,865
2015/2016 :  $99,865
Triggs-Raine, Barbara
University of Manitoba
Evaluation of hyaluronidase 2 as a target for cancer prevention
2014/2015 :  $98,981
2015/2016 :  $98,981
Tsao, Ming-Sound
Ontario Cancer Institute/PMCC - UHN
Oncogenic drivers in KRAS wild type pancreatic ductal adenocarcinoma
2014/2015 :  $99,740
2015/2016 :  $99,740
Turcotte, Simon
Centre hospitalier de l'Université de Montréal
Harnessing the mutation-reactive T-cell response against metastatic colorectal cancer
2014/2015 :  $100,000
2015/2016 :  $50,328
2016/2017 :  $26,144
Wang, Yuzhuo
BC Cancer Agency (Vancouver)
Identification of lead compounds of cytotoxic MTAP substrates for treatment of MTAP-deficient cancers
2014/2015 :  $99,006
2015/2016 :  $99,006
Wouters, Bradly
Ontario Cancer Institute/PMCC - UHN
Targeting lactate and pyruvate transport in tumours
2014/2015 :  $100,000
2015/2016 :  $100,000
Yasufuku, Kazuhiro
The Toronto Hospital (General Division) - UHN
Image-guided localization platform for minimally invasive lung surgery
2014/2015 :  $100,000
2015/2016 :  $100,000

Dernière modification le: 28 juillet 2014